Counselors in Crossnore, NC Accepting Medicare
3 Counselors found. Showing 1 - 3
 Michelle Lea Gordon, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 100 Dar Dr., Crossnore, NC 28616 Phone: 828-733-4305 Fax: 828-733-1704 |
Lauren Staley Stone, LCMHC, LCAS Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 100 Dar Drive, Crossnore, NC 28616 Phone: 828-387-5460 Fax: 336-728-4355 |
Mrs. Alicia Brunson, LPCA Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 Dar Dr, Crossnore, NC 28616 Phone: 828-733-4305 |
News Archive
Breakthrough in Thermal Gradient's fast PCR technology for molecular diagnostics
Thermal Gradient, a Rochester, NY biotech company, announces a breakthrough in its fast PCR technology for molecular diagnostics. PCR is the preferred critical step in virtually all forms of DNA testing.
Next Generation Waters wins "Best New Functional Drink" award
In a category that seems to be expanding by the second, Next Generation Waters is pleased to announce that it has won "Best New Functional Drink" at the 2009 Beverage Innovation Awards, the academy awards of the Beverage Industry. NGW beat out 38 other competitors from 12 different countries including PepsiCo's Lipton Linea, Gatorade's No Artificials, and SoBe's Pure Rush to name a few.
Treadmill training improves functional recovery, neural plasticity after incomplete spinal cord injury
A large body of evidence shows that spinal circuits are significantly affected by training, and that intrinsic circuits that drive locomotor tasks are located in lumbosacral spinal segments in rats with complete spinal cord transection.
Alternative method identified for delivering nusinersen to spinal muscular atrophy patients
A new report has identified an alternative method to deliver nusinersen to patients with spinal muscular atrophy using a subcutaneous intrathecal catheter system configured by connecting an intrathecal catheter to an implantable infusion port.
FDA grants orphan drug designation to Ultragenyx UX003 for treatment of MPS 7
Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.
› Verified 1 days ago
Clinical Social Workers
Counselors
Occupational Therapists
Marriage Counselors